MPLT General Counsel Kristopher Hanson Sells $73K of Stock

MapLight Therapeutics, Inc. (NasdaqGS: MPLT) general counsel Kristopher Hanson unloaded 9,020 shares of company stock on October 15, 2026, according to a Form 4 filing with the SEC.

Inside Kristopher Hanson's MPLT Trade

Hanson sold the shares at a price of $8.08 each, bringing the total value of the transaction to $72,881.60. The stock closed at $8.02 on the day of the transaction. This sale follows earlier insider transactions at the firm, including a purchase by director Troy M Cox and multiple trades by beneficial owner Catalyst4, alongside recent selling activity from other corporate officers.

Other Institutional Activity in MapLight Therapeutics

Large financial firms held steady positions in the biotech firm during mid-year filings. Novo Holdings A/S held 3,686,622 shares valued at roughly $28,386,988. FCPM III Services B.V. maintained its stake of 3,226,400 shares worth about $24,843,279. Nan Fung Group Holdings Limited held 971,253 shares valued at roughly $7,478,647. 5AM Venture Management, LLC held 950,011 shares worth about $7,315,084. Sanofi kept its holdings at 912,041 shares valued at about $7,022,715.

MapLight Therapeutics, Inc. Stock Down 3.9%

MPLT shares recently traded around $7.71 as of October 16, 2026, sitting below the closing price recorded on the day of Hanson's transaction. The company has a market capitalizations of roughly $427.9 million.

Recent Earnings

The clinical-stage drug developer posted a trailing-twelve-month earnings per share of -$6.25, reflecting its ongoing spending on clinical trials. The firm maintains a current ratio of 16.52, pointing to solid short-term liquidity relative to its near-term obligations. Investors will look toward the upcoming earnings release on November 12, 2026, for updates on the company's central nervous system drug pipeline.

Insider Buying and Selling at MapLight Therapeutics, Inc.

Insiders have been active in recent months. Director Troy M Cox bought 15,620 shares on July 28, 2026, at $12.31 per share for a total value of $192,282. Major shareholder Catalyst4 picked up 1,209,225 shares on July 30, 2026, and later added 4,400,000 shares on August 14, 2026, at $11.38 per share worth $50,072,000. Meanwhile, officer James Woodruff Lillie sold 22,082 shares on August 3, 2026, at $12.54 per share for a total value of $276,908. Chief Medical Officer Erin Pennock Foff also recently unloaded 15,355 shares.

Analysts Set New Price Targets

Wall Street firms have adjusted their views on the stock through the summer and fall. On July 28, 2026, Canaccord Genuity maintained its buy rating while lowering its price target to $24.00 from $43.00. On the same day, Morgan Stanley downgraded the stock to equal-weight with a $21.00 target. UBS lowered its rating to neutral on August 10, 2026, cutting its target to $13.00. Needham maintained a buy rating on August 31, 2026, with a $43.00 target, and Guggenheim initiated coverage with a neutral rating on October 6, 2026. Overall, the stock carries a consensus strong buy recommendation from 13 analysts.

About MapLight Therapeutics

MapLight Therapeutics is a clinical-stage biopharmaceutical company based in Redwood City, California, focused on developing treatments for patients suffering from debilitating central nervous system disorders. The company relies on its proprietary discovery platform to target neural circuit dysfunctions.

Bottom Line

Market participants will monitor the upcoming earnings report on November 12, 2026, for pipeline updates. Further Form 4 filings will reveal whether other executives follow Hanson in adjusting their equity holdings.